Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024
February 29 2024 - 7:05AM
Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical
company revolutionizing the delivery of therapies to the back of
the eye through the suprachoroidal space (SCS®), announced today
that its fourth quarter and full year 2023 financial results will
be reported on Tuesday, March 12, 2024 after the close of the
financial markets. Management will host a webcast and conference
call at 4:30 p.m. Eastern Time to discuss the results and provide a
corporate update.
The live and archived webcast may be accessed on
the Clearside website under the Investors section: Events and
Presentations. The live call can be accessed by dialing
888-506-0062 (U.S.) or 973-528-0011 (international) and entering
conference code: 694916. The Company suggests participants join 15
minutes in advance of the event.
About Clearside Biomedical,
Inc.
Clearside Biomedical, Inc. is a
biopharmaceutical company revolutionizing the delivery of therapies
to the back of the eye through the suprachoroidal space (SCS®).
Clearside’s SCS injection platform, utilizing the Company’s
patented SCS Microinjector®, enables an in-office, repeatable,
non-surgical procedure for the targeted and compartmentalized
delivery of a wide variety of therapies to the macula, retina, or
choroid to potentially preserve and improve vision in patients with
sight-threatening eye diseases. Clearside is developing its own
pipeline of small molecule product candidates for administration
via its SCS Microinjector. The Company’s lead program, CLS-AX
(axitinib injectable suspension), for the treatment of neovascular
age-related macular degeneration (wet AMD), is in Phase 2b clinical
testing. Clearside developed and gained approval for its first
product, XIPERE® (triamcinolone acetonide injectable suspension)
for suprachoroidal use, which is available in the U.S. through a
commercial partner. Clearside also strategically partners its SCS
injection platform with companies utilizing other ophthalmic
therapeutic innovations. For more information, please visit
clearsidebio.com.
Investor and Media
Contacts:
Jenny Kobin Remy Bernarda
ir@clearsidebio.com(678) 430-8206
Source: Clearside Biomedical, Inc.
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Jul 2024 to Aug 2024
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Aug 2023 to Aug 2024